Guillain-Barre Syndrome Pipeline Review, H2 2018 - Therapeutics Analysis of 6 Companies & Drug Profiles - ResearchAndMarkets.com
The "Guillain-Barre Syndrome - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Guillain-Barre Syndrome - Overview
- Guillain-Barre Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Guillain-Barre Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
- Akari Therapeutics Plc
- Annexon Inc
- Complement Pharma BV
- CuraVac Inc
- Hansa Medical AB
- Vitality Biopharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4w597h/guillainbarre?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005644/en/